Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136578 · ClinicalTrials.gov registry record · Phase 1
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
A Phase 1 study of Solid Tumours, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00136578 is a Phase 1 study of Solid Tumours that has completed, run by GlaxoSmithKline. The registered enrollment target is 30 participants, below the 143-participant average among 9 other Solid Tumours trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00136578, a Phase 1 study of Solid Tumours, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG SB-715992
Study Locations (2)
Tennessee
- GSK Investigational Site - Nashville
Northumberland
- GSK Investigational Site - Newcastle upon Tyne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-10-20 |
| Est. Completion | 2006-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136578
The ClinicalTrials.gov registry entry for NCT00136578 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 9 other Solid Tumours trials with a reported enrollment target (79% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.
NCT00136578 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Northumberland.
Frequently Asked Questions
What is clinical trial NCT00136578 about?
NCT00136578 is a clinical study titled "Ispinesib In Combination With Carboplatin In Patients With Solid Tumors". The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue ...
What is the current status of trial NCT00136578?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-10-20. Estimated completion is 2006-10-25.
What conditions does trial NCT00136578 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT00136578?
The interventions under investigation include: carboplatin (DRUG), SB-715992 (DRUG).
Who is sponsoring clinical trial NCT00136578?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136578 being conducted?
This trial has 2 study locations across Tennessee, Northumberland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
COMPLETED · Phase 1
-
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
COMPLETED · Phase 1
-
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.